As one example, ABT-199 (venetoclax), which inhibits the interaction of BCL-2 with downstream pro-apoptotic proteins, represents the first small-molecule PPI inhibitor approved for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia (72). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.